Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
This randomized, double-blind, placebo-controlled study is a first-in-human Phase 1 study using two dose levels of an investigational vaccine directed against S. aureus and Candida. The study is designed to evaluate the safety, tolerability and immunogenicity of the investigational vaccine, NDV-3
Epistemonikos ID: 2b36a05b52286c66c147f0abda95f2dd7b4b45e2
First added on: May 06, 2024